Arrowstreet Capital’s AC Immune ACIU Stock Holding History

Arrowstreet Capital’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$554K	Sell	232,953 -172,705	-43%	-$476K	﹤0.01%	1736
2026 Q1	$1.12M	Buy	405,658 +30,035	+8%	+$93.3K	﹤0.01%	1535
2025 Q4	$1.18M	Buy	+375,623	New	+$1.18M	﹤0.01%	1519
2021 Q4	–	Sell	-47,715	Closed	-$320K	–	1415
2021 Q3	$320K	Hold	47,715	–	–	﹤0.01%	1466
2021 Q2	$378K	Sell	47,715 -80,383	-63%	-$556K	﹤0.01%	1719
2021 Q1	$975K	Buy	128,098 +1,391	+1%	+$9.93K	﹤0.01%	1797
2020 Q4	$655K	Sell	126,707 -75,212	-37%	-$384K	﹤0.01%	1948
2020 Q3	$985K	Buy	201,919 +600	+0.3%	+$4.31K	﹤0.01%	1819
2020 Q2	$1.35M	Hold	201,319	–	–	﹤0.01%	1652
2020 Q1	$1.39M	Buy	201,319 +185,919	+1,207%	+$1.45M	﹤0.01%	1196
2019 Q4	$131K	Buy	+15,400	New	+$103K	﹤0.01%	1651
2018 Q4	–	Sell	-21,644	Closed	-$173K	–	1322
2018 Q3	$173K	Buy	+21,644	New	+$218K	﹤0.01%	1029

Other funds holding ACIU

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Arrowstreet Capital's ACIU Position: Q2 2026 in Review

Arrowstreet Capital reduced its AC Immune (ACIU) stake by 43% in Q2 2026, selling an estimated $476K and leaving 232,953 shares worth $554K. The position accounts for ﹤0.01% of the portfolio, ranked #1736.

Arrowstreet Capital first reported a position in ACIU in Q3 2018 and has held it in 12 quarters since. The position peaked at $1.39M in Q1 2020. 43 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.

Arrowstreet Capital held 232,953 shares of AC Immune worth $554K as of Q2 2026.
Arrowstreet Capital sold 172,705 AC Immune shares in Q2 2026, an estimated $476K.
AC Immune made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1736 holding.
Arrowstreet Capital first reported a position in AC Immune in Q3 2018 and has held it in 12 quarters since.
Arrowstreet Capital's AC Immune position peaked at $1.39M in Q1 2020.
43 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.